Teva Pharmaceutical Industries (NYSE:TEVA) EVP Richard Daniell Sells 25,000 Shares of Stock

Key Points

• EVP Richard Daniell sold 25,000 Teva shares at an average of $42.91, worth about $1.07 million. He retained 55,755 shares after the sale, a 30.96% reduction in his position.
• Teva reported quarterly earnings of $0.86 per share, beating the $0.72 analyst consensus, and revenue of $4.39 billion versus $4.23 billion expected; revenue nevertheless declined 1.9% year over year.
• Analyst sentiment was broadly positive: Teva held a “Moderate Buy” consensus rating with an average price target of $48.15, while the stock traded at $43.52 in the report.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) EVP Richard Daniell sold 25,000 shares of the company's stock in a transaction on Monday, November 9th. The shares were sold at an average price of $42.91, for a total value of $1,072,750.00. Following the transaction, the executive vice president directly owned 55,755 shares in the company, valued at $2,392,447.05. This represents a 30.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Richard Daniell also recently made the following trade(s):

• On Wednesday, November 11th, Richard Daniell sold 20,003 shares of Teva Pharmaceutical Industries stock. The stock was sold at an average price of $42.80, for a total value of $856,128.40.

Teva Pharmaceutical Industries Stock Performance

TEVA traded up $0.28 during trading hours on Thursday, hitting $43.52. The stock had a trading volume of 9,218,408 shares, compared to its average volume of 6,859,138. Teva Pharmaceutical Industries Ltd. has a 1 year low of $24.01 and a 1 year high of $44.31. The company's fifty day simple moving average is $39.88 and its 200 day simple moving average is $34.96. The stock has a market cap of $50.72 billion, a PE ratio of 101.22, a price-to-earnings-growth ratio of 3.97 and a beta of 0.97. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 1.59.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Tuesday, November 3rd. The company reported $0.86 earnings per share for the quarter, topping analysts' consensus estimates of $0.72 by $0.14. The firm had revenue of $4.39 billion during the quarter, compared to analyst estimates of $4.23 billion. Teva Pharmaceutical Industries had a net margin of 2.94% and a return on equity of 33.20%. The company's quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter last year, the business earned $0.78 earnings per share. Equities analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.98 earnings per share for the current year.

Analyst Upgrades and Downgrades

TEVA has been the topic of several recent research reports. Oppenheimer increased their target price on Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the stock an "outperform" rating in a research report on Friday, October 9th. HC Wainwright began coverage on Teva Pharmaceutical Industries in a research report on Monday, November 2nd. They issued a "buy" rating and a $52.00 price target for the company. UBS Group boosted their price objective on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a "buy" rating in a research note on Friday, September 4th. Leerink Partners increased their price objective on Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the stock an "outperform" rating in a report on Thursday, November 5th. Finally, TD Cowen boosted their price target on shares of Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the company a "buy" rating in a research report on Wednesday, November 4th. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $48.15.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Root Financial Partners LLC purchased a new stake in Teva Pharmaceutical Industries in the third quarter valued at approximately $33,000. Cornerstone Planning Group LLC grew its stake in Teva Pharmaceutical Industries by 547.1% in the 1st quarter. Cornerstone Planning Group LLC now owns 893 shares of the company's stock worth $27,000 after buying an additional 755 shares in the last quarter. Western Wealth Management LLC purchased a new position in Teva Pharmaceutical Industries in the 1st quarter worth approximately $43,000. Sunbelt Securities Inc. bought a new position in shares of Teva Pharmaceutical Industries in the 1st quarter worth $45,000. Finally, CX Institutional bought a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter worth $54,000. Hedge funds and other institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries News Roundup

Investors following TEVA have been watching these news items:

• Positive Sentiment: Piper Sandler raised its price target to $56 from $44 and upgraded Teva to “overweight,” implying about 28% upside from the cited $43.74 share price. Piper Sandler ratings
• Neutral Sentiment: HC Wainwright made mixed earnings-estimate revisions: it raised its FY2027 EPS forecast to $3.07 from $3.03, but lowered estimates for some individual quarters, including Q4 2026 and Q3 2027. Its overall rating remains “Buy” with a $52 target. Teva analyst information
• Negative Sentiment: Healthcare shares were weaker in Wednesday afternoon trading, with the NYSE Healthcare Index down 0.6%, creating a possible sector-level headwind for TEVA. Healthcare sector update

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.